Last reviewed · How we verify
Jyseleca (FILGOTINIB)
Jyseleca (Filgotinib) is a small molecule modality developed by Gilead Sciences Ireland UC, targeting the Tyrosine-protein kinase JAK1. It is used to treat Rheumatoid arthritis and Ulcerative colitis. The commercial status of Jyseleca is patented, with Gilead Sciences Ireland UC being the current owner. Key safety considerations include the potential for increased risk of infections and malignancies. Jyseleca works by inhibiting the JAK1 enzyme, which plays a crucial role in the signaling pathways of various immune cells.
At a glance
| Generic name | FILGOTINIB |
|---|---|
| Sponsor | Gilead Sciences Ireland UC |
| Target | Tyrosine-protein kinase JAK1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
- Rheumatoid arthritis
- Ulcerative colitis
Common side effects
Key clinical trials
- Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
- A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis (PHASE3)
- A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice (PHASE4)
- Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
- Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France
- Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) (PHASE1)
- A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (PHASE3)
- A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jyseleca CI brief — competitive landscape report
- Jyseleca updates RSS · CI watch RSS
- Gilead Sciences Ireland UC portfolio CI